NO20061966L - Bicyclo [3.1.1.] Heptane-substituted benzimidazolone and quinazolinone derivatives as agonists for human ORL1 receptors - Google Patents

Bicyclo [3.1.1.] Heptane-substituted benzimidazolone and quinazolinone derivatives as agonists for human ORL1 receptors

Info

Publication number
NO20061966L
NO20061966L NO20061966A NO20061966A NO20061966L NO 20061966 L NO20061966 L NO 20061966L NO 20061966 A NO20061966 A NO 20061966A NO 20061966 A NO20061966 A NO 20061966A NO 20061966 L NO20061966 L NO 20061966L
Authority
NO
Norway
Prior art keywords
agonists
quinazolinone derivatives
bicyclo
heptane
receptors
Prior art date
Application number
NO20061966A
Other languages
Norwegian (no)
Inventor
Herman Heinrich Va Stuivenberg
Jacobus Antonius Joseph Hartog
Gustaaf Johan Mar Scharrenburg
Tinka Tuinstra
Samuel David
Daniel Jasserand
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/052392 external-priority patent/WO2005032547A1/en
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20061966L publication Critical patent/NO20061966L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen vedrører en gruppe hydronopol substituerte benzimidazolon- og kinazolinonderivater som er agonister for humane ORL1 (nociceptin) reseptorer. Oppfinnelsen vedrører også fremstillingen av disse forbindelsene, farmasøytiske sammensetninger som inneholder en farmakologisk aktiv mengde av minst en av disse nye benzimidazolon og kinazolinonderivatene som en aktiv ingrediens, så vel som anvendelsen av disse farmasøytiske sammensetningene for behandling av forstyrrelser hvorved ORL1 reseptorer er involvert. Der symbolene har betydningene som er angitt i beskrivelsen. Oppfinnelsen vedrører forbindelser med den generelle formel (1)This invention relates to a group of hydronopoly substituted benzimidazolone and quinazolinone derivatives which are agonists of human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and the quinazolinone derivatives as an active ingredient, as well as the use of these pharmaceutical compositions for the treatment of disorders involving ORL1 receptors. Where the symbols have the meanings given in the description. The invention relates to compounds of the general formula (1)

NO20061966A 2003-10-03 2006-05-03 Bicyclo [3.1.1.] Heptane-substituted benzimidazolone and quinazolinone derivatives as agonists for human ORL1 receptors NO20061966L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50794703P 2003-10-03 2003-10-03
EP03103671 2003-10-03
PCT/EP2004/052392 WO2005032547A1 (en) 2003-10-03 2004-10-01 Bicyclo`3.1.1!heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors

Publications (1)

Publication Number Publication Date
NO20061966L true NO20061966L (en) 2006-06-29

Family

ID=34424772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061966A NO20061966L (en) 2003-10-03 2006-05-03 Bicyclo [3.1.1.] Heptane-substituted benzimidazolone and quinazolinone derivatives as agonists for human ORL1 receptors

Country Status (3)

Country Link
KR (1) KR20060134927A (en)
IL (1) IL173435A0 (en)
NO (1) NO20061966L (en)

Also Published As

Publication number Publication date
IL173435A0 (en) 2006-06-11
KR20060134927A (en) 2006-12-28

Similar Documents

Publication Publication Date Title
NO20080670L (en) Substituted piperazines as metabotrophic glutamate receptor antagonists
ATE485269T1 (en) C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC DISORDERS
NO20063599L (en) Further heterocyclic compounds and their use as metabotrophic glutamate receptor antagonists
UA84896C2 (en) Hydronopol derivatives as agonists on human orl1 receptors
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
NO20052496L (en) Selected CGRP antagonists, methods for their preparation and use thereof as drugs.
EE200300403A (en) N-substituted Non-Aromatic Heterocyclic Compound, Pharmaceutical Composition Containing It, and Use of the Compound as a Pharmaceutical
NO20092342L (en) Azaspiroderivativater
UA83868C2 (en) Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
NO20091766L (en) Spiro-piperidine
EA200801184A1 (en) DERIVATIVES OF PIPEREDIN-4-IL-PYRIDAZIN-3-ILAMINE AS FAST DISCRETING ANTAGONISTS OF DOPAMINE 2 RECEPTOR
NO20072684L (en) Conjugates with anti-inflammatory activity
DK1725536T3 (en) Imidazoline derivatives with CB1 antagonistic activity
NO20075637L (en) 4-Phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as drugs for the treatment of infertility
NO20091831L (en) indoles
NO20080669L (en) Acetylene piperazines as metabotrophic glutamate receptor antagonists
NO20091832L (en) Indoles that act via receptor antagonists
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
NO20080671L (en) Bicyclic piperazines as metabotrophic glutamate receptor antagonists
IS8096A (en) Use of carbamazepine derivatives to treat patient agitation is dementia sufferers
NO20055758L (en) Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists
NO20060969L (en) Benzoxazinone derivative sulfonamide compounds, their preparation and use as drugs
NO20063138L (en) Hydronopoly derivatives as agonists in human ORL1 receptors
NO20052491L (en) New Vitronectin Receptor Antagonist Derivatives, Methods for their Preparation, Their Use as Drugs and Pharmaceutical Compositions Containing the Same
NO20090125L (en) Benzimidazole derivatives to be used as antagonist for CB1 receptor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application